Exhibit 99.1 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update · In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint · Early 2023, strong validation of CureVac’s proprietary mRNA technology platform from positive preliminary Phase 1 data in COVID-19 and flu in collaboration with GSK o Monovalent modified COVID-19 candidate CV0501 demonstrate ...